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Altered Trafficking of Mutant Connexin32
Suzanne M. Descheˆnes, Jessica L. Walcott, Tamara L. Wexler, Steven S. Scherer, and Kenneth H. Fischbeck
Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104
We examined the cellular localization of nine different con-
nexin32 (Cx32) mutants associated with X-linked Charcot–
Marie–Tooth disease (CMTX) in communication-incompetent
mammalian cells. Cx32 mRNA was made, but little or no protein
was detected in one class of mutants. In another class of
mutants, Cx32 protein was detectable in the cytoplasm and at
the cell surface, where it appeared as plaques and punctate
staining. Cx32 immunoreactivity in a third class of mutants was
restricted to the cytoplasm, where it often colocalized with the
Golgi apparatus. Our studies suggest that CMTX mutations
have a predominant effect on the trafficking of Cx32 protein,
resulting in a potentially toxic cytoplasmic accumulation of
Cx32 in these cells. These results and evidence of cytoplasmic
accumulation of other mutated myelin proteins suggest that
diseases affecting myelinating cells may share a common
pathophysiology.
Key words: Cx32; gap junctions; X-linked Charcot–Marie–
Tooth disease; protein trafficking; Golgi apparatus; myelin;
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X-linked Charcot–Marie–Tooth disease (CMTX) is a form of
hereditary motor and sensory neuropathy with clinical features
that include progressive weakness and atrophy of distal limb
muscles, loss of reflexes, sensory loss, and reduced nerve conduc-
tion velocity. In males affected with CMTX, the first clinical signs
of the disease arise in late childhood or adolescence and lead to
moderate disability by the third decade of life, whereas heterozy-
gous women may be more mildly affected or asymptomatic (for
review, see Descheˆnes et al., 1996).
CMTX is caused by mutations in the gene for connexin32
(Cx32; also known as gap junction gene b1), a member of the
family of gap junction proteins. Gap junctions are clusters of
intercellular channels in plasma membranes that allow the pas-
sage of ions and small molecules between closely apposed cells
(for review, see Bruzzone et al., 1996; Goodenough et al., 1996).
Cx32 is expressed in many cell types (Bruzzone et al., 1996),
including myelinating Schwann cells of peripheral nerve, where it
localizes to noncompact myelin at the paranodal region and
Schmidt–Lanterman incisures (Bergoffen et al., 1993; Scherer et
al., 1995). In these structures, Cx32 is thought to form reflexive
gap junctions between layers of the Schwann cell membrane
(Bergoffen et al., 1993). The restriction of the CMTX phenotype
to the peripheral nervous system implies that myelinating
Schwann cells are particularly susceptible to Cx32 mutations.
Myelinating cells are also the targets of mutations in other
myelin genes (Suter and Snipes, 1995; Scherer, 1997). For exam-
ple, mutations in peripheral myelin protein 22 kDa (PMP-22) and
myelin protein zero (P0) directly affect Schwann cells and are
associated with inherited demyelinating neuropathies, such as
CMT types 1A and 1B, hereditary neuropathy with liability to
pressure palsies, and Dejerine–Sottas disease. Missense muta-
tions in proteolipid protein (PLP) may kill oligodendrocytes, the
myelin-producing cells of the CNS, and result in Pelizaeus–
Merzbacher disease (PMD) (Nave and Boespflug-Tanguy, 1996).
It is not yet known whether myelin gene mutants adversely affect
myelinating Schwann cells via the same mechanisms.
To date, .90 different mutations in .120 CMTX families have
been described (Scherer et al., 1997); their distribution through-
out the coding region of Cx32 suggests that every domain of the
protein is important for its normal function in peripheral nerve.
Studies in Xenopus oocytes (Bruzzone et al., 1994; Rabadan-
Diehl et al., 1994) and in HeLa cells (Omori et al., 1996) have
shown that some Cx32 mutants associated with CMTX are non-
functional and may also exert dominant-negative effects on other
connexins coexpressed in the same cell, whereas other mutants
remain functional in these systems. Here, we report the effects of
nine CMTX mutations on the trafficking and cellular localization
of Cx32 stably expressed in a subclone of rat pheochromocytoma
(PC12J) cells, a communication-incompetent mammalian cell
line. We have defined three distinct effects of these CMTX
mutations on Cx32 protein trafficking, suggesting that different
defects in membrane protein transport in myelinating Schwann
cells may have similar consequences.
MATERIALS AND METHODS
Cx32 mutations. The following abbreviations are used for Cx32 mutations
studied in this paper: Gly12Ser (G12S), Arg15Gln (R15Q), Val63Ile
(V63I), Val139Met (V139M), Arg142Trp (R142W), 175 frameshift
(175fs), Glu186Lys (E186K), Glu208Lys (E208K), and Arg220stop codon
(R220Stop). The CMTX families bearing these mutations have been
described elsewhere [V139M (Heimler et al., 1978); G12S (Fryns and
Van den Berghe, 1980); 175fs (Rozear et al., 1987); R142W and E186K
(Bergoffen et al., 1993); and R15Q, V63I, E208K, and R220Stop (Fair-
weather et al., 1994)]. Table 1 summarizes the phenotypes of these
families; the severity of the clinical phenotype was based on a review of
medical records and the published literature. Fifty percent of females at
risk for inheriting the disease allele (symptomatic at-risk females, col-
umn 3) are expected to be symptomatic in families in which CMTX is
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dominant. The family with the 175fs mutation has the most severe
phenotype, with affected men losing ambulation and many heterozygous
women having symptoms nearly as severe as those of the men. Families
with the G12S, R142W, E186K, and E208K mutations have moderate to
severe symptoms, with reduced nerve conduction velocities in both males
and heterozygous females. In families with the R15Q, V63I, V139M, and
R220Stop mutations, the phenotype is mild to moderate in both men and
women.
Cx32 mutants 175fs, R142W, and E186K were cloned previously by
Bruzzone et al. (1994). The coding regions were excised from the BglII site
of pSP64T (Bruzzone et al., 1994) and cloned into the BamHI site of
pREP9 (Invitrogen, San Diego, CA). The coding regions of wild-type Cx32
and CMTX mutants G12S, R15Q, V63I, V139M, E208K, and R220Stop
were amplified from the genomic DNA of an unaffected man and male
CMTX patients, respectively, by PCR (one cycle of 94°C for 10 min; 30
cycles of 94°C for 1 min, 59°C for 1 min, and 72°C for 50 sec) with Vent
polymerase (New England Biolabs, Beverly, MA) in a PTC-100 thermal
controller (MJ Research, Watertown, MA). The reaction buffer included
the following reagents at their final concentrations: 400 mM dNTPs, 1 mM
primers, 20% Luria–Bertani medium (Cease et al., 1994), 10% DMSO, and
0.5 U of Vent polymerase. The two pairs of PCR primers with restriction
sites that were used to amplify a segment containing the translational start
site and stop codon are listed as follows: for mutants G12S and V139M,
sense Cx321.Bam 59-CGCGGATCCGGCAGGATGAACTGGACAG
GT-39 and antisense Cx32A1.Eco 59-CCGGAATTCATGGCAGGTT
GCCTGGTATG-39, and for all other mutants, sense Cx32F.Kpn
59-CGGGGTACCGGCAGGATGAACTGGACAGG-39 and antisense
Cx32R.Bam 59-GGCGGATCCATGGCAGGTTGCCTGGTATG-39. The
PCR products were electrophoresed on agarose gels, excised, purified by
Geneclean (BIO 101, Vista, CA), and digested with BamHI and EcoRI
(G12S and V139M) or KpnI and BamHI (all other mutants). The G12S and
V139M inserts were ligated into the BamHI and EcoRI sites of pBS S/K
and later excised from pBS S/K with NotI and XhoI for cloning into the
same sites in pREP9. All other mutant inserts were ligated into the KpnI
and BamHI sites of pREP9. The constructs were sequenced on both strands
at least twice by automated sequencing (University of Pennsylvania De-
partment of Genetics DNA Sequencing Facility) to verify the sequence.
Cell culture and stable transfection. The subclone of rat pheochromo-
cytoma cells (PC12J; a gift of Dr. David Spray, Albert Einstein College
of Medicine, Bronx, NY) that was used in this study expresses no
endogenous Cx32 protein or mRNA (see Fig. 2 A,C,E) and very low
amounts of Cx37 protein (data not shown). These cells are not electri-
cally coupled, as determined by dual whole-cell patch-clamp analysis (D.
Spray, personal communication). The cells were cultured in RPMI 1640
supplemented with 10% horse serum, 5% fetal bovine serum, and pen-
icillin and streptomycin in a 37°C, 5% CO2 incubator. PC12J cells were
stably transfected with 5–35 mg of plasmid DNA and Lipofectin reagent
(Life Technologies, Gaithersburg, MD) according to the manufacturer’s
protocol. For all transfections but those with G12S and V139M mutants,
35–55 independent clones were picked and expanded 2–3 weeks after
selection in 400 mg/ml G418 (Life Technologies). For the G12S and V139M
mutants, transfected cells were maintained in selective medium rather than
isolating clones by limiting dilution. To test the effect of reduced growth
temperatures on the expression of Cx32 protein, we also grew a subset of
clones at 23–25°C on a bench top or in a 5% CO2 incubator.
Northern blotting. RNA was isolated from confluent cultures of cells
growing in 10 cm dishes using RNAzol B reagent (Tel-Test, Friends-
wood, TX) according to the manufacturer’s directions. Ten microgram
samples of total RNA were electrophoresed in 1% agarose gels contain-
ing 6.6% (v/v) formaldehyde and transferred and cross-linked as de-
scribed previously (Scherer et al., 1995). Blots were prehybridized, hy-
bridized, and washed using standard techniques (Sambrook, 1989), with
a final wash in 23 SSC at 65°C. A full-length human Cx32 cDNA probe
was prepared by isolating the 893 bp insert from the wild-type Cx32
construct described above. A full-length cDNA probe of rat glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) (Fort et al., 1985) was
similarly prepared by restriction endonuclease digestion. Both inserts
were electrophoresed on agarose gels, excised, purified by Geneclean
(BIO 101), and labeled with 32P by random primer extension using the
Rediprime kit (Amersham, Arlington Heights, IL).
Immunoblotting. Cells were grown to confluence in 100 mm plates and
harvested in cold Dulbecco’s PBS lacking calcium and magnesium ions
(Life Technologies). The cell pellet was either stored at 280°C or lysed
directly in ice-cold 50 mM Tris, pH 7.0, 1% SDS, and 0.017 mg/ml
phenylmethylsulfonyl fluoride (Sigma, St. Louis, MO), followed by a
brief sonication on ice with a sonic dismembrator (Fisher Scientific,
Pittsburgh, PA). Rat liver homogenate was prepared by pulverizing
snap-frozen adult rat liver with a steel mortar and pestle on dry ice,
homogenizing in 20 mM NaOH, and sonicating. Total protein concen-
trations were quantitated with a modified Lowry assay (DC Protein
Assay Kit; Bio-Rad, Hercules, CA). One hundred microgram samples of
protein lysate for each clone and 1 ml of the rat liver homogenate were
loaded onto 12% SDS–polyacrylamide gels after a 5–15 min incubation
in sample buffer at room temperature (RT), electrophoresed, and trans-
ferred to Immobilon–polyvinylidene fluoride membrane (Millipore,
Bedford, MA) using a semidry blotting unit (Fisher) according to Mil-
lipore’s recommendations. The blots were blocked (5% powdered skim
milk and 0.5% Tween-20 in Tris-buffered saline) 1 hr at RT and incu-
bated overnight at 4°C in a polyclonal antiserum diluted 1:5000 (donated
by David Paul, Harvard Medical School, Cambridge, MA) (Paul, 1986),
monoclonal antibody M12.13 diluted 1:10 [supernatant donated by David
Paul (Goodenough et al., 1988)], or monoclonal antibody 7C6.C7 (undi-
luted supernatant or ascites-diluted 1:1000; donated by Elliot Hertzberg,
Albert Einstein College of Medicine, Bronx, NY) (Nagy et al., 1996).
After washes in blocking solution, the blots were incubated in appropri-
ate dilutions of peroxidase-coupled secondary antibodies against mouse
or rabbit IgG (Jackson ImmunoResearch, West Grove, PA) for 1 hr at
RT. After washes in blocking solution and Tris-buffered saline contain-
ing 0.5% Tween-20, blots were visualized by enhanced chemilumines-
cence (Amersham) according to the manufacturer’s protocols.




heterozygotes Phenotypeb Cellular localization of Cx32
G12S Moderate (F) to marked (M)
reductions
1/10 Severe Cytoplasm
R15Q 20 (M); 30 (F) 0/3 Moderate Plasma membrane
V63I 41 (M) 2/7 Mild Plasma membrane and cytoplasm
V139M 28–32 (M) 9/15 Moderate Plasma membrane and cytoplasm
R142W 27–35 (M) 2/5 Moderate to severe Cytoplasm
175fs 26–39 (M); 37–64 (F) 9/29 Severe No detectable protein
E186K 39–40 (M); 35–48 (F) 1/12 Moderate Cytoplasm
E208K Not known 1/3 Moderate to severe Cytoplasm
R220Stop 48–50 (M) 2/2 Moderate Plasma membrane and cytoplasm
Moderate indicates significant weakness and atrophy of distal muscles in all limbs, high stepping gait, and early onset, but not a serious impediment to a normal lifestyle in
men and high-arched feet and mild weakness and atrophy in distal legs in women. Severe indicates marked weakness and atrophy of distal muscles in all limbs, sensory loss,
and significant impediments to mobility that necessitate canes and wheelchairs in men and high-arched feet and sensory disturbances in women.
a NCV (nerve conduction velocity) is based on studies in one or more affected individuals [M (male); F (female)]; normal NCV is .50 m/sec (Nicholson and Nash, 1993).
b Mild indicates weakness and atrophy of distal muscles in all limbs but no difficulty walking in men and thin ankles and high-arched feet in women.
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Immunocytochemistry. Eight-well plastic chamber slides (Lab-Tek
Permanox-coated slides; Nunc, Naperville, IL) were coated with 10
mg/ml poly-L-lysine (Sigma), air dried, and seeded with clones expressing
various Cx32 mutants. In some experiments, when cells reached 75%
confluence, the medium was aspirated and replaced with medium con-
taining 15 mg/ml brefeldin A (BFA, dissolved in 100% ethanol; Sigma)
for 1 hr at 37°C in a 5% CO2 incubator. Control slides were incubated
with medium containing the equivalent volume of ethanol. Cells were
fixed in 95% ethanol /5% glacial acetic acid at 220°C for 10 min. After
washes in PBS lacking calcium and magnesium ions, the slides were
blocked in 5% bovine serum albumin, 10% fetal bovine serum, 0.1%
Triton X-100, 0.1 M NaH2PO4 , 0.1 M Na2HPO4 , and 0.01% sodium azide
at 37°C for 30–60 min. Incubations in the following antibodies were done
for 24–72 hr at 4°C in a humidified chamber: M12.13 (undiluted super-
natant), 7C6.C7 (undiluted supernatant or ascites-diluted 1:250), poly-
clonal antiserum B1J (diluted 1:100; donated by Norton Gilula, Scripps
Research Institute, La Jolla, CA) (Milks et al., 1988), monoclonal anti-
body 10A8 (the supernatant was used either undiluted or diluted 1:150;
donated by Nicholas Gonatas, University of Pennsylvania, Philadelphia,
PA) (Gonatas et al., 1989), and a polyclonal antibody against rat liver
Golgi a-mannosidase II (diluted 1:500; donated by Marilyn Farquhar,
University of California, San Diego, CA) (Velasco et al., 1993). After
washes in PBS, slides were incubated with 1:100 dilutions of rhodamine-
or fluorescein-conjugated donkey anti-mouse or -rabbit IgG antibodies
(Jackson ImmunoResearch). Slides were mounted in Vectashield (Vec-
tor Laboratories, Burlingame, CA) and visualized with a scanning laser
confocal microscope (Leica, Nussloch, Germany), using ScanWare 5.10
software to generate ;1-mm-thick optical sections.
RESULTS
Analysis of mutant Cx32 expression
The CMTX mutations shown in Figure 1 are a subset of .90
different mutations that are distributed throughout the Cx32
protein (Scherer et al., 1997). They were chosen for this study
because they occur in different domains of Cx32 and might be
expected to have distinct effects on its localization and function.
PC12J cells were stably transfected with each construct, and
41–80 clones were picked for each mutant. Clones were screened
for Cx32 expression by immunoblotting and/or immunocyto-
chemistry. Cx32 protein was not detected in parental cells (Fig.
2A, lane 1) or in cells transfected with the vector alone (Fig. 2A,
lanes 2–3). Relative to other mutants and wild-type Cx32, few
clones expressed detectable protein for mutants R142W and
E186K (Table 2). The 175fs mutant is predicted to produce a
truncated protein of 27 kDa, but no protein was detectable on
immunoblots of 56 independent clones; three of these clones are
shown in Figure 2B. On the other hand, cells transfected with
R220Stop expressed a truncated protein at the expected size of 25
kDa (Fig. 2C, lanes 1–3) that was absent in parental cells and
untransfected cells (Fig. 2C, lanes 4–6). In clones expressing the
other mutants, Cx32 migrated at the same position on denaturing
polyacrylamide gels (Fig. 2D, lanes 3–12) as did Cx32 isolated
from rat liver and cells transfected with wild-type Cx32 (Fig. 2D,
lanes 1–2, respectively; V139M not shown). Cells transfected with
G12S had no detectable Cx32 (data not shown). Northern blot
analysis was performed to determine whether the absent or low-
level Cx32 expression in G12S, R142W, and 175fs clones was
because of mutational effects at the mRNA or protein levels.
Transcripts of the appropriate size and amount relative to wild-
type Cx32 transcripts (Fig. 2E, lane 5) were detected in four 175fs
clones (Fig. 2E, lanes 1–4) and two R142W clones (including
116.38; data not shown) but not in parental cells (Fig. 2E, lane 6)
or cells transfected with G12S (data not shown). Immunocyto-
chemical analysis of the four 175fs clones with an antibody that
recognizes the cytoplasmic loop of Cx32 further confirmed the
lack of Cx32 protein expression (data not shown). Except for the
175fs and G12S mutants, these results demonstrated that mutant
Cx32 protein was expressed and migrated at the expected molec-
ular weight.
Cellular localization
We examined the localization of wild-type and mutant Cx32 by
indirect immunofluorescence using scanning laser confocal mi-
croscopy. Cells expressing wild-type Cx32 had plaques and punc-
tate staining, especially in regions of cell–cell contact, as well as
punctate cytoplasmic staining (Fig. 3B). Clones expressing R15Q
had a staining pattern that was indistinguishable from that of cells
expressing wild-type Cx32 (Fig. 3C). The localization of Cx32 in
the plasma membrane of clones expressing either wild-type Cx32
or R15Q was independent of the level of protein expression (data
not shown).
In cells expressing the V63I, V139M, and R220Stop mutants,
Cx32 was localized in the plasma membrane in a punctate or
plaque-like staining pattern (Fig. 3D,E,G) and in the cytoplasm as
a focal immunoreactivity (Fig. 3D–F). The predominant pattern
in many V63I and R220Stop clones expressing lesser amounts of
Cx32, however, was a diffuse cytoplasmic immunoreactivity (data
not shown). Because cytoplasmic immunoreactivity was consis-
tently seen in multiple clones expressing different amounts of
mutant Cx32 (as determined by immunoblot), overexpression of
Cx32 can be eliminated as the cause of cytoplasmic accumulation
in the V63I and R220Stop clones.
Cx32 immunoreactivity was entirely cytoplasmic in clones ex-
pressing G12S (Fig. 3H), R142W (Fig. 3I), E186K (Fig. 4A), and
E208K (Figs. 3J, 4D), regardless of the level of protein expression
(data not shown). Via immunocytochemistry, few cells transfected
Figure 1. Diagram of Cx32, with the mutations studied in this paper
indicated by arrows. Asterisks indicate conserved cysteine residues.
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with G12S and R142W were found to express Cx32 protein, ac-
counting for its complete (G12S) or near absence (R142W) on
immunoblots. To determine the intracellular compartment in
which mutant Cx32 was located, we performed double immunola-
beling with antibodies against resident proteins of the Golgi appa-
ratus (Gonatas et al., 1989; Velasco et al., 1993). In cells expressing
E186K, Cx32 appeared to be exclusively localized in the Golgi
apparatus (Fig. 4A–C). Although the E208K mutant sometimes
colocalized with the Golgi apparatus (Fig. 4D–F), it was predom-
inantly found in a diffuse cytoplasmic pattern that overlapped but
was not limited to the Golgi apparatus (Fig. 3J). In clones express-
ing lower amounts of E208K protein, Cx32 staining appeared
entirely diffuse. Although double immunolabeling was not per-
formed for G12S and R142W, the identical cytoplasmic immuno-
reactivities of G12S, R142W, and E186K (Figs. 3H,I, 4A) suggest
that G12S and R142W were also localized in the Golgi apparatus
in the few cells expressing the protein.
To confirm further the localization of E186K and E208K in the
Golgi apparatus, we treated cells expressing each mutant with
brefeldin A (BFA), which blocks anterograde transport into the
Golgi compartment, thereby causing a redistribution of Golgi
resident proteins to the endoplasmic reticulum (ER) (for review,
see Hunziker et al., 1992; Klausner et al., 1992). BFA did not
dramatically alter the localization of Cx32 protein in clones
expressing the E208K mutant (data not shown). BFA did, how-
ever, change Cx32 immunoreactivity in cells expressing the
E186K mutant from a concise localization (Fig. 5A) to a diffuse,
weaker-staining pattern (Fig. 5B) that paralleled changes in the
localization of MG160 (Fig. 5C,D, respectively), a resident pro-
tein of the medial cisternae of the Golgi apparatus (Gonatas et
al., 1989). Taken together, these data demonstrate that substitu-
tions at residues 12, 142, 186, and 208 may block the proper
trafficking of Cx32 to the plasma membrane.
DISCUSSION
Three classes of CMTX mutations
Via immunocytochemical localization of Cx32, we have defined
three different effects of CMTX mutations, which represent dif-
Figure 2. Analysis of Cx32 expression in PC12J cells stably transfected
with normal and mutated Cx32 cDNAs. A, As negative controls for B,
immunoblots of the parental cells (P; lane 1) and two clones transfected
with the vector alone (V; lanes 2–3, clones pREP9.6.1 and pREP9.6.4)
were hybridized with a polyclonal antiserum (Lola) that recognizes an
epitope in the cytoplasmic loop of Cx32. The bands seen across all lanes
in A and B, including a high molecular weight band (asterisk), are proteins
nonspecifically detected by Lola. B, Immunoblots of three clones trans-
fected with 175fs (lanes 1–3, clones 5117.6.1, 5117.4.9, and 5117.4.3) were
hybridized with Lola. C, Immunoblots of three clones expressing various
amounts of R220Stop protein (lanes 1–3), the parental cells (P; lane 4 ),
and two clones transfected with the vector alone (V; lanes 5–6 ) were
performed with a mouse monoclonal antibody against the cytoplasmic
loop (M12.13). An arrow indicates truncated Cx32. The two bands seen
across all lanes (asterisks) are proteins nonspecifically detected by the
M12.13 antibody. D, Immunoblots of rat liver (1; lane 1) and represen-
tative clones transfected with wild-type Cx32 (WT; lane 2, clone 517.4.7),
R15Q (lanes 3–4, clones 15.23 and 15.57), V63I (lanes 5–6, clones 63.36
and 63.55), R142W (lanes 7–8, clones 116.41 and 116.38), E186K (lanes
9–10, clones 412.5 and 414.10), and E208K (lanes 11–12, clones 208.47 and
208.49) were performed with a mouse monoclonal antibody that also
recognizes the C terminal (7C6.C7). Dashes indicate the positions of
molecular weight markers of 46 and 30 kDa, respectively. E, Northern
blots of four clones transfected with 175fs (lanes 1–4, 5117.2.3, 5117.4.9,
5117.2.10, and 5117.4.3), one clone expressing wild-type Cx32 (WT; lane
5, 517.4.7), and the parental cells (P; lane 6 ) were performed using a
full-length, wild-type human Cx32 cDNA probe. The Cx32 transcripts are
of the expected size (;1.3 kb). The same blots were stripped and rehy-
bridized with a full-length rat GAPDH cDNA probe to assess the relative
quantity of RNA in each lane. The dashes indicate the positions of 18S
rRNA (;2.4 kb). For immunoblots, the single and double arrowheads
represent the positions of the monomeric and dimeric forms of rat liver
Cx32 on the same gels. The migration of rat liver Cx32 is slower because
the homogenate was prepared in a different lysis buffer relative to that
used for the cell lysates (see Materials and Methods).
Table 2. List of clones picked under selective pressure after stable







pREP9 41 33 (80) 0
Wild-type 54 41 (76) 16
R15Q 68 41 (60) 20
V63I 72 38 (53) 23
R142W 80 51 (64) 6 (2 low-moderate)b,c
175fs 62 56 (90) 0
E186K 78 54 (69) 9 (4 low-moderate)b
E208K 72 45 (62) 26
R220Stop 52 41 (78) 16
a Assessment of expression level was based on signal intensity in immunocytochem-
ical analyses and/or on band intensity on immunoblots, relative to that seen with the
wild-type clone 517.4.7. As determined through immunocytochemistry, Cx32 ex-
pression was heterogeneous in all clones; not all cells in a given population expressed
Cx32 protein, even though they were maintained under selective pressure.
b Relative to other constructs, few clones expressing these Cx32 mutants were
isolated, and the Cx32 expression level in these clones was generally lower and more
heterogeneous than the level in clones expressing wild-type or mutant Cx32.
c The extent of Cx32 expression in this clone was especially low, accounting for the
weak Cx32 bands on immunoblots (see Figure 2).
9080 J. Neurosci., December 1, 1997, 17(23):9077–9084 Descheˆnes et al. • Mutant Connexin32
ferent classes of mutants. One class is represented by Cx32
mutant 175fs, a frameshift that truncates Cx32 by 43 amino acids
and changes the last 67 residues, including the fourth transmem-
brane domain. Although clones expressing this mutant had the
same amount of transcript as a wild-type Cx32 clone (Fig. 2E),
little or no Cx32 protein was detected, suggesting that this
CMTX mutation interferes with translation or results in the rapid
degradation of Cx32 protein. This finding contrasts with the
expression and cell surface localization of the same mutant in
Xenopus oocytes (Bruzzone et al., 1994), indicating that protein
stability and/or trafficking differ between the two cell types.
Because our results were obtained from cultured mammalian
cells, they are probably more relevant to the disease mechanism.
The family bearing this mutation has a particularly severe phe-
notype, in which older male patients are often wheelchair-bound
and many females at risk for carrying the disease allele are
symptomatic (Table 1; Rozear et al., 1987; Bergoffen et al., 1993).
Another class of CMTX mutations is defined by Cx32 mutants
R15Q, V63I, V139M, and R220Stop, in which at least some Cx32
is properly routed to the cell surface. It may be that the mutant
Cx32 that arrives at the plasma membrane is not capable of
forming functional gap junctions or that a fraction of the protein
is misrouted, with dominant-negative or toxic effects on Schwann
cells. The V139M and R220Stop mutants were studied previously
by Omori et al. (1996). Our findings with V139M are consistent
with their report, but the localization of R220Stop differed in that
it was also in the cytoplasm. It may be that the amount of
R220Stop in our cells is higher than the amount was in this
previous study, resulting in the formation of intracellular gap
junctions, as shown by Kumar et al. (1995). Nonetheless, the
identification of the specific effects of R15Q, V63I, V139M, and
R220Stop on the function of gap junctions awaits electrophysio-
logical and dye-coupling studies and examination of the mutant
proteins in the myelin sheath.
A third class of CMTX mutations, which includes G12S,
R142W, E186K, and E208K, is characterized by the cytoplasmic
accumulation of Cx32 and the absence of cell surface expression.
Our findings indicate that these CMTX mutations alter Cx32
trafficking so that the protein accumulates in intracellular com-
partments such as the Golgi apparatus (e.g., G12S, R142W, and
E186K) or in other sites such as the ER or lysosomes (e.g.,
E208K). We postulate that transmembrane domains 3 (TM3) and
4 (TM4) play important roles in Cx32 trafficking. A similar role
for Cx32 transmembrane domains has been proposed by Leube,
who showed that swapping the transmembrane domains of Cx32
and synaptophysin altered the routing of the hybrid proteins
(Leube, 1995). In a previous study of the R142W and E186K
mutants in Xenopus oocytes, Cx32 was shown to localize to the
plasma membrane (Bruzzone et al., 1994). Again, the disparities
in protein targeting between Xenopus oocytes and PC12J cells
likely relate to cell-type and species differences in connexin
processing. Finally, because the N terminal has been implicated in
the insertion of connexins into membranes (Bennett et al., 1991;
Falk et al., 1994), the cytoplasmic retention of the G12S mutant
may result from improper membrane insertion.
The nature of the particular changes in the third class of
CMTX mutations may provide additional clues to their adverse
effects. Two of the mutations, E186K and E208K, change the
polarity of a charged residue (2 to 1) that flanks TM4, whereas
the third mutation R142W replaces a charged residue with an
uncharged amino acid in TM3. Because charged residues in
transmembrane domains are important for retention of proteins
in the ER and the Golgi apparatus (Bonifacino et al., 1991;
Machamer et al., 1993), these CMTX mutations might cause
conformational changes within the Cx32 molecule or affect inter-
actions between Cx32 monomers forming a hemichannel. The
relationship between hemichannel assembly and the site of mu-
tant Cx32 accumulation may be complex, considering the differ-
ent paradigms for connexin oligomerization (Musil and Good-
enough, 1993; Kumar et al., 1995). Because the substitution at
residue 139 is conservative, few if any effects on membrane
insertion or protein trafficking would be expected. Further mu-
tational analysis will be necessary to determine which domains of
Cx32 are most important for its proper oligomerization and
transport in the cell.
Figure 3. Localization of wild-type Cx32 and CMTX mutants in PC12J
cells by indirect immunofluorescence using scanning laser confocal mi-
croscopy. Immunocytochemistry was performed with 7C6.C7 for all
clones but R220Stop, for which M12.13 was used. A, Untransfected cells,
PC12J. B, Wild-type Cx32, clone 517.4.7. C, R15Q, clone 15.38. D, V63I,
clone 63.55. E, V139M, nonclonal cells. F, R220Stop, clone 220.37. G,
R220Stop, clone 220.37. H, G12S, nonclonal cells. I, R142W, clone 116.38.
J, E208K, clone 208.37. The magnification of J is higher to show greater
cytoplasmic detail. Note that the diffuse staining seen in clone 208.37 is
the predominant pattern observed in all clones expressing E208K. Scale
bars, 10 mm.
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Cx32 mutations and the CMTX phenotype
What is the effect of trafficking defects on the CMTX disease
phenotype and its pattern of inheritance? An association between
Cx32 mutations and disease severity has been suggested by Ion-
asescu et al. (1996), but it is difficult to draw strict correlations
between genotype and clinical phenotype because of the variable
expressivity of the disease (e.g., Table 1). An additional compli-
cation is the incomplete penetrance of the disease in women. For
example, 50% of women at risk for inheriting the disease allele
(Table 1, symptomatic at-risk female heterozygotes) should be
symptomatic when CMTX is dominantly inherited. Although
cellular localization does not correlate with disease penetrance in
females, it may parallel the clinical variability observed in CMTX
patients. At least some mutant Cx32 from families with mild to
moderate symptoms (Table 1) reaches the cell surface in trans-
fected cells (e.g., R15Q, V63I, V139M, and R220Stop). The most
severe neuropathy is associated with 175fs (Table 1), for which
little or no protein is detectable in transfected cells; the disease
mechanism may be a simple loss of function. Although Cx32-null
mice do not have an overt phenotype, clear evidence of demyeli-
nation is manifest by 4 months of age (Anzini et al., 1997),
indicating that loss of Cx32 is associated with changes in the
myelin sheath. It may be that mice are less sensitive than are
humans to Cx32 loss. Investigations of additional loss-of-function
mutations in Cx32 will be necessary to resolve this apparent
difference.
In the families with moderate to severe clinical phenotypes
(e.g., G12S, R142W, and E208K), Cx32 protein trafficking is
defective in vitro. This association suggests that these Cx32 mu-
tants may have dominant-negative effects in peripheral nerve.
Toxic interactions with other proteins such as chaperones or
proteins of the trafficking machinery might also occur in com-
partments in which mutant Cx32 accumulates. Other studies have
focused on interactions between normal and mutant Cx32
(Rabadan-Diehl et al., 1994; Omori et al., 1996), but these are not
likely to exist in myelinating Schwann cells of women because
Cx32 is subject to X-inactivation (Scherer et al., 1997).
The possibility of dominant-negative interactions with other
connexins in the same cell, however, is supported by at least two
lines of evidence. First, Bruzzone et al. (1994) showed that
mutant R142W can exert dominant-negative effects on Cx26 in
Xenopus oocytes, which is coexpressed with Cx32 in many tissues
(Bruzzone et al., 1996). Second, the expression of unidentified
connexins in cultured Schwann cells has been reported (Chanson
et al., 1993; Chandross et al., 1995, 1996); mutant Cx32 may
abrogate the normal function of these other connexins in myeli-
nating Schwann cells.
Dominant effects of mutations in myelin proteins have been
noted in other inherited diseases of myelin (Suter and Snipes,
1995; Scherer, 1997). In the Trembler mouse, for example, a point
mutation in PMP-22 causes a severe dysmyelinating phenotype
(Suter et al., 1992) and results in the accumulation of P0 in the
Figure 4. Localization of Cx32 mutants E186K and E208K in PC12J cells by indirect immunofluorescence using scanning laser confocal microscopy.
A–C, Cells expressing E186K (clone 414.10) were double-stained with the mouse monoclonal antibody 7C6.C7 against Cx32 (A; rhodamine) and a
polyclonal antiserum against rat a-mannosidase II (MnII ) (B; fluorescein). A and B are superimposed in C. D–F, Cells expressing E208K (clone 208.49)
were double-stained with the polyclonal antiserum B1J against Cx32 (D; rhodamine) and the monoclonal antibody 10A8 against MG160 (E; fluorescein).
D and E are superimposed in F. The characteristically punctate staining of E186K obtained with 7C6.C7 (see Fig. 5; data not shown) is difficult to see
because of high background staining contributed by the a-mannosidase II antibody; arrowheads are used to indicate Cx32 immunoreactivity in the
cytoplasm of these cells. Note the absence of Cx32 at the cell surface in these two mutants. Scale bars, 10 mm.
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Golgi apparatus (Heath et al., 1991). An accumulation of mutant
PLP in the ER was observed in oligodendrocytes of jimpy mice
(Roussel et al., 1987), which also have a severe dysmyelinating
phenotype (for review, see Nave and Boespflug-Tanguy, 1996).
Gow et al. (1994) transfected the jimpy allele and human PLP
missense mutants into Cos cells and found that they, too, caused
defects in protein trafficking. A more detailed study of PLP
alleles involved in different subtypes of PMD (for review, see
Nave and Boespflug-Tanguy, 1996) revealed that connatal (more
severe) PMD correlated with ER retention of both mutant PLP
and its alternatively spliced product DM-20, whereas classical
(less severe) PMD was associated with ER accumulation of full-
length PLP but not of DM-20 (Gow and Lazzarini, 1996). Unlike
their milder counterparts, DM-20 alleles associated with connatal
PMD could not facilitate transport of PLP to the cell surface,
indicating a dominant-negative effect of these mutations on PLP
(Gow and Lazzarini, 1996). Taken together, these findings and
our results suggest that inherited diseases of myelin share a
common pathophysiology in which mutant protein retained in
intracellular compartments has deleterious effects on the protein
folding, degradation, or trafficking machineries. Myelin-
producing cells may be particularly susceptible to damage caused
by misrouted protein, perhaps accounting in part for the tissue
specificity of these diseases.
As with all model systems, it is difficult to know for certain
whether our results reflect the mechanism of disease in vivo. The
myelinating Schwann cells that are affected by Cx32 mutations
have a phenotype and architecture that are different from PC12J
cells and a more complex pattern of expression of plasma mem-
brane proteins. Analysis of mutant Cx32 in in vivo models, such as
transgenic and knock-out mice, will shed light on these issues and
help to define further the normal role of gap junctions in periph-
eral nerve.
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